We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+12.64%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$3.53B
AUM Growth
+$116M
Cap. Flow
-$73.8M
Cap. Flow %
-2.09%
Top 10 Hldgs %
47.92%
Holding
99
New
17
Increased
28
Reduced
21
Closed
18

Top Buys

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$51.2M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$50.1M
3
FOLD
Amicus Therapeutics
FOLD
+$40.3M
4
CNC icon
Centene
CNC
+$37.3M
5
STOK icon
Stoke Therapeutics
STOK
+$27.4M

Top Sells

Rank Stock Value
1
IFRX icon
InflaRx
IFRX
+$82.5M
2
ARRY
Array Biopharma Inc
ARRY
+$62.3M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$49.3M
4
PEN icon
Penumbra
PEN
+$47.5M
5
XNCR icon
Xencor
XNCR
+$46.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.51%
2 Miscellaneous 2.32%
3 Financials 2.17%
4 Energy 0.01%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
1
DELISTED
Array Biopharma Inc
ARRY
$405M 11.47%
8,752,254
-2,218,264
-20% -$62.3M
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$284M 8.05%
22,792,634
+3,176,572
+16% +$40.3M
FATE icon
3
Fate Therapeutics
FATE
$291M
$210M 5.95%
10,359,666
– –
ARGX icon
4
argenx
ARGX
$64B
$151M 4.28%
1,068,832
+49,771
+5% +$6.32M
QURE icon
5
uniQure
QURE
$3.38B
$130M 3.69%
1,669,525
+362,003
+28% +$23.1M
BOLD
6
DELISTED
Audentes Therapeutics, Inc
BOLD
$113M 3.18%
2,972,167
+236,900
+9% +$9.1M
EPZM
7
DELISTED
Epizyme, Inc
EPZM
$110M 3.1%
8,729,142
+1,035,122
+13% +$13.3M
ALLK
8
DELISTED
Allakos
ALLK
$99.7M 2.82%
2,300,301
+465,891
+25% +$19.1M
ALDR
9
DELISTED
Alder Biopharmaceuticals
ALDR
$97M 2.75%
8,244,896
– –
ATRA icon
10
Atara Biotherapeutics
ATRA
$92.3M
$92.5M 2.62%
184,037
+4,620
+3% +$3.26M
TCDA
11
DELISTED
Tricida, Inc. Common Stock
TCDA
$76.8M 2.17%
1,945,200
+1,454,900
+297% +$51.2M
EHTH icon
12
eHealth
EHTH
$38.4M
$76.5M 2.17%
888,705
-333,700
-27% -$22.5M
BMY icon
13
Bristol-Myers Squibb
BMY
$136B
$75.7M 2.14%
1,669,400
+69,700
+4% +$3.25M
TNDM icon
14
Tandem Diabetes Care
TNDM
$1.49B
$75.2M 2.13%
1,166,032
+310,100
+36% +$20M
RGNX icon
15
Regenxbio
RGNX
$638M
$71.5M 2.02%
1,391,376
-28,966
-2% -$1.45M
WVE icon
16
Wave Life Sciences
WVE
$993M
$71M 2.01%
2,719,707
-111,800
-4% -$3.14M
WMGI
17
DELISTED
Wright Medical Group Inc
WMGI
$70.7M 2%
2,372,157
-501,943
-17% -$15.3M
XNCR icon
18
Xencor
XNCR
$1.94B
$66M 1.87%
1,612,798
-1,423,805
-47% -$46.8M
SRPT icon
19
Sarepta Therapeutics
SRPT
$2.2B
$62.6M 1.77%
+412,000
New +$50.1M
ELV icon
20
Elevance Health
ELV
$85.5B
$51.8M 1.47%
183,500
+6,800
+4% +$1.86M
CELG
21
DELISTED
Celgene Corp
CELG
$51.5M 1.46%
557,000
+21,300
+4% +$2.02M
CLVS
22
DELISTED
Clovis Oncology, Inc.
CLVS
$51.5M 1.46%
3,462,300
-1,101,629
-24% -$19.9M
DCPH
23
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$50.1M 1.42%
2,223,376
+594,723
+37% +$13.9M
SRRK icon
24
Scholar Rock
SRRK
$7.04B
$46.3M 1.31%
2,920,389
+869,300
+42% +$16.1M
KRYS icon
25
Krystal Biotech
KRYS
$10.4B
$43.5M 1.23%
1,080,300
+755,800
+233% +$24.7M
1
2 3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2019 Portfolio in Review

As of Q2 2019, Redmile Group held 99 positions worth $3.53B, up 3.4% from $3.42B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Redmile Group's Q2 2019 filing shows 17 new, 28 increased, 21 reduced and 18 closed positions. Its largest new stake was Sarepta Therapeutics: 412,000 shares worth $62.6M. The largest sale was InflaRx, an estimated $82.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Miscellaneous and Financials.

  • Redmile Group's largest Q2 2019 buy was Sarepta Therapeutics: 412,000 shares worth $62.6M.
  • Redmile Group added most to Tricida, Inc. Common Stock in Q2 2019, an estimated $51.2M increase.
  • Redmile Group's biggest Q2 2019 reduction was Array Biopharma Inc, cutting an estimated $62.3M.
  • Redmile Group fully exited InflaRx in Q2 2019, selling an estimated $82.5M.
  • Redmile Group's ten largest holdings make up 48% of its $3.53B portfolio in Q2 2019.
  • Redmile Group opened 17 new positions and closed 18 in Q2 2019.
  • Redmile Group's portfolio value rose 3.4% quarter-over-quarter to $3.53B.

Based on Redmile Group's 13F filing for Q2 2019, filed 14 Aug 2019.